These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27990653)

  • 1. Population Pharmacokinetic and Pharmacodynamic Modeling of Epacadostat in Patients With Advanced Solid Malignancies.
    Shi JG; Bowman KJ; Chen X; Maleski J; Leopold L; Yeleswaram S
    J Clin Pharmacol; 2017 Jun; 57(6):720-729. PubMed ID: 27990653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Target exposure and pharmacodynamics study of the indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor epacadostat in the CT26 mouse tumor model.
    Poncelet L; Ait-Belkacem R; Marillier R; Gomes B; Stauber J
    J Pharm Biomed Anal; 2019 Jun; 170():220-227. PubMed ID: 30933897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.
    Beatty GL; O'Dwyer PJ; Clark J; Shi JG; Bowman KJ; Scherle PA; Newton RC; Schaub R; Maleski J; Leopold L; Gajewski TF
    Clin Cancer Res; 2017 Jul; 23(13):3269-3276. PubMed ID: 28053021
    [No Abstract]   [Full Text] [Related]  

  • 4. A randomised, open-label, phase 2 study of the IDO1 inhibitor epacadostat (INCB024360) versus tamoxifen as therapy for biochemically recurrent (CA-125 relapse)-only epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer.
    Kristeleit R; Davidenko I; Shirinkin V; El-Khouly F; Bondarenko I; Goodheart MJ; Gorbunova V; Penning CA; Shi JG; Liu X; Newton RC; Zhao Y; Maleski J; Leopold L; Schilder RJ
    Gynecol Oncol; 2017 Sep; 146(3):484-490. PubMed ID: 28698009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemo-immunotherapy by nanoliposomal epacadostat and docetaxel combination to IDO1 inhibition and tumor microenvironment suppression.
    Khoshkhabar R; Yazdani M; Hoda Alavizadeh S; Saberi Z; Arabi L; Reza Jaafari M
    Int Immunopharmacol; 2024 Aug; 137():112437. PubMed ID: 38870880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential Underprediction of Warfarin Drug Interaction From Conventional Interaction Studies and Risk Mitigation: A Case Study With Epacadostat, an IDO1 Inhibitor.
    Shi JG; Chen X; Punwani NG; Williams WV; Yeleswaram S
    J Clin Pharmacol; 2016 Nov; 56(11):1344-1354. PubMed ID: 26990117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of S-EPA, and its inhibition on indoleamine 2,3-dioxgenase: a case of sulfur-substitution affecting distributions in blood cells.
    Wang W; Zhuang X; Sun H; Dong L; Liu Z; Du G; Ye L; Tian J
    Xenobiotica; 2019 Nov; 49(11):1338-1343. PubMed ID: 30507339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison study of different indoleamine-2,3 dioxygenase inhibitors from the perspective of pharmacodynamic effects.
    Jiang X; Li X; Zheng S; Du G; Ma J; Zhang L; Wang H; Tian J
    Int J Immunopathol Pharmacol; 2020; 34():2058738420950584. PubMed ID: 32962460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors.
    Song X; Sun P; Wang J; Guo W; Wang Y; Meng LH; Liu H
    Eur J Med Chem; 2020 Mar; 189():112059. PubMed ID: 31981851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2,3-dioxygenase 1 and tryptophan 2,3-dioxygenase 2, in patients with advanced solid tumors.
    Naing A; Eder JP; Piha-Paul SA; Gimmi C; Hussey E; Zhang S; Hildebrand V; Hosagrahara V; Habermehl C; Moisan J; Papadopoulos KP
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32843490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.
    Labadie BW; Bao R; Luke JJ
    Clin Cancer Res; 2019 Mar; 25(5):1462-1471. PubMed ID: 30377198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of S-epacadostat, an indoleamine 2,3-dioxygenase 1 inhibitor, in dog plasma and identification of its metabolites in vivo and in vitro.
    Zhang Y; Li X; Sun Y; Liu X; Wang W; Tian J
    Biomed Chromatogr; 2021 Dec; 35(12):e5226. PubMed ID: 34388261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, Synthesis and Biological Evaluation of Novel 1,2,5-Oxadiazol-3- Carboximidamide Derivatives as Indoleamine 2, 3-Dioxygenase 1 (IDO1) Inhibitors.
    Xia Z; Nan Y; Liu C; Lin G; Gu K; Chen C; Zhao W; Ju D; Dong X
    Anticancer Agents Med Chem; 2020; 20(13):1592-1603. PubMed ID: 32496990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Determination of kynurnine and tryptophan, biomarkers of indoleamine 2,3-dioxygenase by LC-MS/MS in plasma and tumor.
    Wang W; Zhuang X; Liu W; Dong L; Sun H; Du G; Ye L
    Bioanalysis; 2018 Aug; 10(16):1335-1344. PubMed ID: 30130131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indoleamine 2,3-Dioxygenase 1 Inhibitor-Loaded Nanosheets Enhance CAR-T Cell Function in Esophageal Squamous Cell Carcinoma.
    Shao J; Hou L; Liu J; Liu Y; Ning J; Zhao Q; Zhang Y
    Front Immunol; 2021; 12():661357. PubMed ID: 33828565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kynurenine/Tryptophan Ratio as a Potential Blood-Based Biomarker in Non-Small Cell Lung Cancer.
    Mandarano M; Orecchini E; Bellezza G; Vannucci J; Ludovini V; Baglivo S; Tofanetti FR; Chiari R; Loreti E; Puma F; Sidoni A; Belladonna ML
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells.
    Jochems C; Fantini M; Fernando RI; Kwilas AR; Donahue RN; Lepone LM; Grenga I; Kim YS; Brechbiel MW; Gulley JL; Madan RA; Heery CR; Hodge JW; Newton R; Schlom J; Tsang KY
    Oncotarget; 2016 Jun; 7(25):37762-37772. PubMed ID: 27192116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, biological evaluation of urea substituted 1,2,5-oxadiazole-3-carboximidamides as novel indoleamine 2,3-dioxygenase-1 (IDO1) inhibitors.
    Ye K; Wang K; Wang T; Tang H; Wang L; Zhang W; Jiang S; Zhang X; Zhang K
    Eur J Med Chem; 2023 Mar; 250():115217. PubMed ID: 36842272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.
    Zhai L; Spranger S; Binder DC; Gritsina G; Lauing KL; Giles FJ; Wainwright DA
    Clin Cancer Res; 2015 Dec; 21(24):5427-33. PubMed ID: 26519060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-regulation of indoleamine 2,3-dioxygenase 1 (IDO1) expression and catalytic activity is associated with immunosuppression and poor prognosis in penile squamous cell carcinoma patients.
    Zhou QH; Han H; Lu JB; Liu TY; Huang KB; Deng CZ; Li ZS; Chen JP; Yao K; Qin ZK; Liu ZW; Li YH; Guo SJ; Ye YL; Zhou FJ; Liu RY
    Cancer Commun (Lond); 2020 Jan; 40(1):3-15. PubMed ID: 32125093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.